NCT06780137 2026-03-16
MK-6070-002
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT06992609 2026-03-02
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT07005128 2026-02-27
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting
NCT06898957 2026-02-05
(DeLLphi-310)
Amgen
Phase 1 Recruiting
NCT07339059 2026-01-30
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07174583 2026-01-23
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT06769126 2026-01-22
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting
NCT05617963 2025-06-15
DURVALUNG
UNICANCER
Phase 2 Recruiting
NCT06223711 2024-04-05
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Universität des Saarlandes
Phase 2 Recruiting